David E.I. Pyott's Insider Trades & SAST Disclosures
David E.I. Pyott's most recent trade in Alnylam Pharmaceuticals Inc was a trade of 17,560 Stock Option (right to buy) done . Disclosure was reported to the exchange on June 24, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern David E.I. Pyott.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Alnylam Pharmaceuticals Inc | David E.I. Pyott | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jun 2024 | 17,560 | 7,440 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | David E.I. Pyott | Director | Sale of securities on an exchange or to another person at price $ 220.00 per share. | 24 Jun 2024 | 17,560 | 15,026 (0%) | 0% | 220 | 3,863,200 | Common Stock |
| Alnylam Pharmaceuticals Inc | David E.I. Pyott | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 88.95 per share. | 24 Jun 2024 | 17,560 | 17,696 (0%) | 0% | 89.0 | 1,561,962 | Common Stock |
| Alnylam Pharmaceuticals Inc | David E.I. Pyott | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jun 2024 | 7,470 | 3,780 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | David E.I. Pyott | Director | Sale of securities on an exchange or to another person at price $ 222.00 per share. | 24 Jun 2024 | 7,470 | 136 (0%) | 0% | 222 | 1,658,340 | Common Stock |
| Alnylam Pharmaceuticals Inc | David E.I. Pyott | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 71.99 per share. | 24 Jun 2024 | 7,470 | 32,586 (0%) | 0% | 72.0 | 537,765 | Common Stock |
| Alnylam Pharmaceuticals Inc | David E.I. Pyott | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 70.20 per share. | 24 Jun 2024 | 7,420 | 25,116 (0%) | 0% | 70.2 | 520,884 | Common Stock |
| Alnylam Pharmaceuticals Inc | David E.I. Pyott | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jun 2024 | 7,420 | 3,830 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | David E.I. Pyott | Director | Sale of securities on an exchange or to another person at price $ 221.00 per share. | 24 Jun 2024 | 7,420 | 7,606 (0%) | 0% | 221 | 1,639,820 | Common Stock |
| Pliant Therapeutics Inc | David E.I. Pyott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 26,764 | 26,764 | - | - | Common Stock (Right to Buy) | |
| Biomarin Pharmaceutical In... | David E.I. Pyott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2024 | 4,720 | 49,750 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharmaceuticals Inc | David E.I. Pyott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 5,228 | 5,228 | - | - | Stock Option (right to buy) | |
| Pliant Therapeutics Inc | David E.I. Pyott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 14,000 | 14,000 | - | - | Stock Option (Right to Buy) | |
| Biomarin Pharmaceutical In... | David E.I. Pyott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2023 | 4,190 | 45,030 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharmaceuticals Inc | David E.I. Pyott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 3,454 | 3,454 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | David E.I. Pyott | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2023 | 136 | 136 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharmaceuticals Inc | David E.I. Pyott | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2023 | 136 | 0 | - | - | Restricted Stock Units | |
| Pliant Therapeutics Inc | David E.I. Pyott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Biomarin Pharmaceutical In... | David E.I. Pyott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2022 | 4,980 | 40,840 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharmaceuticals Inc | David E.I. Pyott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2022 | 5,153 | 5,153 | - | - | Stock Option (right to buy) | |
| Alnylam Pharmaceuticals Inc | David E.I. Pyott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2022 | 136 | 136 | - | - | Restricted Stock Units | |
| Alnylam Pharmaceuticals Inc | David E.I. Pyott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2021 | 4,032 | 4,032 | - | - | Stock Option (right to buy) | |
| Pliant Therapeutics Inc | David E.I. Pyott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2021 | 13,286 | 13,286 | - | - | Stock Option (right to buy) | |
| Biomarin Pharmaceutical In... | David E.I. Pyott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2021 | 5,120 | 35,860 (0%) | 0% | 0 | Common Stock | |
| Pliant Therapeutics Inc | David E.I. Pyott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2021 | 26,573 | 26,573 | - | - | Stock Option (right to buy) | |
| Biomarin Pharmaceutical In... | David E.I. Pyott | Director | Purchase of securities on an exchange or from another person at price $ 78.22 per share. | 31 Aug 2020 | 11,900 | 29,840 (0%) | 0% | 78.2 | 930,760 | Common Stock |
| Biomarin Pharmaceutical In... | David E.I. Pyott | Director | Purchase of securities on an exchange or from another person at price $ 78.84 per share. | 31 Aug 2020 | 900 | 30,740 (0%) | 0% | 78.8 | 70,955 | Common Stock |
| Alnylam Pharmaceuticals Inc | David E.I. Pyott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2020 | 4,581 | 4,581 | - | - | Stock Option (right to buy) | |
| Biomarin Pharmaceutical In... | David E.I. Pyott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2020 | 4,300 | 17,940 (0%) | 0% | 0 | Common Stock | |
| Avery Dennison Corp. | David E.I. Pyott | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 107.56 per share. | 23 Apr 2020 | 1,414 | 18,684 (0%) | 0% | 107.6 | 152,090 | Common Stock |
| Avery Dennison Corp. | David E.I. Pyott | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Apr 2020 | 1,414 | 0 | - | - | 2019 Director RSU Award |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges